More than 40 years have passed since the CDC reported the first cases of HIV in the United States. In that time, we’ve ...
Gilead has chosen a partner for lenacapavir in the race to develop new low-frequency treatments for HIV. | Gilead has chosen ...
Abbvie (($ABBV)) announced an update on their ongoing clinical study. AbbVie recently updated its clinical study titled A ...
Leaders in HIV research highlighted the critical role of that research has played in advancing HIV science over the past 40 years. In a commentary in Nature Medicine, they explained how U.S.-funded ...
Merck's two-drug HIV regimen doravirine/islatravir maintained viral suppression and matched Gilead's Biktarvy in Phase 3 ...
B/F/TAF shows lower ART switching rates and higher persistence among HIV patients, especially those with mental health or ...
Investor's Business Daily on MSN
Gilead Sciences Dives As HIV Drug Misses Bullish Buy-Side Expectations
Gilead stock slumped late Thursday on soft product sales and lighter-than-expected revenue from its newcomer HIV prevention ...
The NIH funding will help address a "traditional barrier" to health care, says Elizabeth Evans, professor of community health ...
More than 230 people became infected with HIV in Indiana, worsened by delayed action from former Gov. Mike Pence. Experts and ...
A new UCLA study reveals that breast milk from women living with HIV contains significantly lower levels of tryptophan, an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback